Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design

Breast

Volumn 21, Issue 1, 2012, Pages 20-26

  Eiermann, W ^a   Bergh, J ^b,c   Cardoso, F ^d   Conte, P ^e   Crown, J ^f   Curtin, N J ^g   Gligorov, J ^h   Gusterson, B ⁱ   Joensuu, H ^j   Linderholm, B K ^k   Martin, M ^l   Penault Llorca, F ^m   Pestalozzi, B C ⁿ   Razis, E ^o   Sotiriou, C ^p   Tjulandin, S ^q   Viale, G ^r  

^a Women s Clinic   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d Champalimaud Cancer Center   (Portugal)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h HÔPITAL TENON   (France)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^k SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^l UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^m CENTRE JEAN PERRIN   (France)

ⁿ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^o HYGEIA HOSPITAL   (Greece)

^p JULES BORDET INSTITUTE   (Belgium)

^q N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^r UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Basal like; Breast cancer; Her2; Histopathology; Oestrogen receptor; Triple negative

Indexed keywords

BIS 201; CARBOPLATIN; CISPLATIN; CLAUDIN; CYCLOPHOSPHAMIDE; CYTOKERATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; INIPARIB; METHOTREXATE; PROGESTERONE RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CANCER RELAPSE; CENTROMERE; CHROMOSOME 17; CLINICAL TRIAL (TOPIC); DISTANT METASTASIS; FALSE POSITIVE RESULT; FAMILY HISTORY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DOSAGE; GENE MUTATION; GENETIC SCREENING; HER2 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; MINIMAL RESIDUAL DISEASE; ONCOGENE; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOSENSITIVITY; REVIEW; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER;

EID: 84856334753     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.09.006     Document Type: Review

References (74)

1. Carey L., Winer E., Viale G., Cameron D., Gianni L. Triple-negative breast cancer: disease entity or title of convenience. Nat Rev Clin Oncol 2010, Published on doi:10.1038/nrclinonc.2010.154.
2. Berrada N., Delaloge S., Andre F. Treatment of triple negative metastatic breast cancer: toward individualized targeted treatments or chemosensitisation?. Ann Oncol 2010, 21(Suppl 7):vii30-35.
3. Santana-Davila R., Perez E.A. Treatment options for patients with triple negative breast cancer. JHematol Oncol 2010 Published October 2010, 27. 10.1186/1756-8722-3-42.
4. Badve S., Dabbs D.J., Schnitt S.J., Baehne F.L., Decker T., Eusebi V., et al. Basal like and triple negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 2011, 24:157-167.
5. Rastelli F., Biancanelli S., Falzetta A., Martignetti A., Casic C., Bascioni R., et al. Triple-negative breast cancer: current state of the art. Tumori 2010, 96:875-888.
6. Hudis C.A., Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011, 16(Suppl 1):1-11.
7. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434.
8. Heitz F., Harter P., Lueck H.J., Fissler-Eckhoff A., Lorenz-Salehi F., Scheij-Bertram S., et al. Triple negative and Her2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009, 45:2792-2798.
9. Liedtke C., Mazouni C., Hess K.R., Andre F., Tordai A., Mejia J.A., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. JClin Oncol 2008, 26:1275-1281.
10. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
11. Seal M.D., Chia S.K. What is the difference between triple-negative and basal breast cancers?. Cancer J 2010, 16:12-16.
12. Reis-Filho J.S., Tutt A.N. Triple-negative tumours: a critical review. Histopathology 2008, 52:108-118.
13. Rakha E.A., Elsheikh S.E., Aleskandarany M.A., Habashi H.O., Green A.R., Powe D.G., et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009, 15:2302-2310.
14. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple negative breast cancer. NEngl J Med 2010, 1938-1948.
15. Hammond M.E., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Path Lab Med 2010, 134:907-932.
16. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thurlimann S., Senn H.J., et al. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2009, 2009(20):1319-1329.
17. Viale G., Regan M.M., Maiorano E., Mastropasqua M.G., Dell'Orto P., Rasmussen B.B., et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. JClin Oncol 2007, 25:3846-3852.
18. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378(77):1-84. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
19. Dowsett M., Dunbier A.K. Emerging biomarkers and new understanding of predictive markers in personalized therapy for breast cancer. Clin Cancer Res 2008, 14:8019-8026.
20. Park S., Koo J., Park H.S., Kim J.H., Choi S.Y., Lee J.H., et al. Expression of androgen receptors in primary breast cancer. Ann Oncol 2010, 21:488-492.
21. Peters A.A., Buchanan G., Ricciardelli C., Bianco-Miotto T., Centenera M.M., Harris J.M., et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009, 69:6131-6140.
22. Ryden L., Haglund M., Bendahl P.O., Hatschek T., Kolaric A., Kovacs A., et al. Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer - a national survey performed at pathology departments in Sweden. Acta Oncologica 2009, 48:860-866.
23. Sauter G., Lee J., Bartlett J.M., Slamon D.J., Press M.F. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. JClin Oncol 2009, 27:1323-1333.
24. Pauletti G., Dandekar S., Rong H., Ramos L., Peng H., Seshadri R., et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. JClin Oncol 2000, 18:3651-3664.
25. Zujewski J.A. Build quality in" - HER2 testing in the real world. JNatnl Cancer Inst 2002, 94:788-789.
26. Vance G.H., Barry T.S., Bloom K.J., Fitzgibbons P.L., Hicks D.G., Jenkins R.B., et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 2009, 133:611-612.
27. Iurisci I., Cottu P., Ngo C., Lae M., Pierga J.-Y., Dieras V., et al. Heterogeneous amplification of HER2 is rare but clinically significant event in invasive ductal carcinoma. Cancer Res 2009, 59(24 suppl). Abs 6034.
28. Paik S., Kim C., Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. NEngl J Med 2008, 358:1409-1411.
29. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
30. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
31. Parker J.S., Mullins M., Cheang M.C., Leung S., Voduc D., Vickery T., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. JClin Oncol 2009, 27:1160-1167.
32. Laakso M., Tanner M., Nilsson J., Wiklund T., Erikstein B., Kellokumpu-Lehtinen P., et al. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 2006, 12:4185-4191.
33. Gusterson B. Do "basal-like" breast cancers really exist?. Nat Rev Cancer 2009, 9:128-134.
34. Collins L.C., Martyniak A., Kandel M.J., Stadler Z.K., Masciari S., Miron A., et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple negative breast cancers. Am J Surg Pathol 2009, 33:1093-1097.
35. Rakha E., Ellis I., Reis-Filho J. Are triple-negative and basal-like breast cancer synonymous?. Clin Cancer Res 2008, 14. 6-8-619.
36. Cheang M.C., Voduc D., Bajdik C., Leung S., McKinney S., Chia S.K., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14:1368-1376.
37. Choi Y.L., Oh E., Park S., Kim Y., Park Y.H., Song K., et al. Triple-negative, basal-like and quintuple negative breast cancers: better prediction model for survival. BMC Cancer 2010, 10:507. 10.1186/1471.2407-10-507.
38. Prat A., Parker S.J., Karginova O., Fan C., Livasy C., Herschkowitz J.I., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68.
39. Constantinidou A., Jones R.L., Reis-Filho J.S. Beyond triple negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther 2010, 10:1197-1213.
40. Marchio C., Weigelt B., Reis-Filho J.S. Adenoid cystic carcinomas of the breast and salivary glands (or "The strange case of Dr Jekyll and Mr Hyde" of exocrine gland carcinomas). JClin Pathol 2010, 63:220-228.
41. Wells C.A., El-Ayat G.A. Non-operative breast pathology: apocrine lesions. JClin Pathol 2007, 60:1313-1320.
42. Ellis I.O., Lee A.H. The prognostic significance of inflammation and medullary histological subtype in invasive carcinoma of the breast. Eur J Cancer 2009, 45:1780-1787.
43. Pusztai L., Viale G., Kelly C.M., Hudis C.A. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010, 15:1164-1168.
44. Simmons C., Miller N., Geddie W., Gianfelice D., Oldfield M., Dranitsaris G., et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009, 20:1499-1504.
45. Lindstrom L.S., Karlsson E., Wilking U., Bergh J. Discordance in hormone receptor and HER2 status in breast cancer during tumor progression 2010, San Antonio Breast Cancer Symposium, Abstract S3-S5.
46. Carey L. Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer. JClin Oncol 2010, 28:361-363.
47. Byrski T., Gronwald J., Huzarski T., Grzybowska E., Budryk M., Stawicka M., et al. Pathologic complete response rates in young women with BRCA-1 positive breast cancers after neoadjuvant chemotherapy. JClin Oncol 2010, 28:375-379.
48. Somer R., Farengo-Clark D., Patel A., Schwarting R., Grana G., Rodier E., et al. Screening for BRCA1 mutations in patients with triple negative breast cancer and basal phenotype. Cancer Res 2009, 69. Abs 4075.
49. Fostira F., Tsitiadou M., Gogas H., Pertesi M., Yannoukakos D., Bournakis E., et al. Prevalence of BRCA1 mutations among 284 women with triple-negative breast cancer. JClin Oncol 2010, 28. Abs 1511.
50. Kwon J.S., Gutierrez-Barrera A.M., Young D., Sun C.C., Daniels M.S., Lu K.H., et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. JClin Oncol 2010, 28:4214-4220.
51. Dragun A.E., Pan J., Rai S.N., Kruse B., Jain D. Locoregional recurrence in patients with triple-negative breast cancer: preliminary results of a single institution study. Am J Clin Oncol 2010.
52. Voduc K.D., Cheang M.C., Tyldesley S., Gelmon K., Nielsen T.O., Kennecke H., et al. Breast cancer subtypes and the risk of local and regional relapse. JClin Oncol 2010, 28:1684-1689.
53. Parikh R.R., Housman D., Yang Q., Toppmeyer D., Wilson L.D., Haffty B.G., et al. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. Int J Radiaion Oncol Biol Phys 2008, 72:1056-1063.
54. Haffty B.G., Yang Q., Reiss M., Kearney T., Higgins S.A., Weidhaas J., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. JClin Oncol 2006, 24:5652-5657.
55. Freedman G.M., Anderson P.R., Li T., Nicolaou N. Locoregional recurrence of triple negative breast cancer after breast-conserving surgery and radiation. Cancer 2009, 115:946-951.
56. Isakoff S.J. Triple negative breast cancer: role of specific chemotherapy agents. Cancer J 2010, 16:53-61.
57. Colleoni M., Cole B.F., Viale G., Regan M.M., Price K.N., Maiorano E., et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. JClin Oncol 2010, 28:2966-2973.
58. Weigelt B., Kreike B., Reis-Filho J.S. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 2009, 117:273-280.
59. Von Minckwitz G., Untch M., Nuesch E., Loibl S., Kaufmann M., Kummel S., et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neoadjuvant chemotherapy trials. Breast Cancer Res Treat 2011, 125:145-156.
60. Laporte S., Jones S., Chapelle C., Jaquin J.-P., Martin M. Consistency of effect of docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer independent of nodal status: meta-analysis of 12 randomized clinical trials 2009, San Antonio Breast Cancer Symposium, abstract 605.
61. Chang H.R., Glaspy J., Allison M.A., Kass F.C., Elashoff R., Chung D.U., Gornbein J., et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 2010, 116:4227-4237.
62. Warm M., Kates R., Grosse-Onnebrink E., Stoff-Khalili M., Hoopmann M., Mallmann P., et al. Impact of tumor biology, particularly triple negative status, on response to pre-operative, sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer. Anticancer Res 2010, 30:4251-4259.
63. Amir E., Seruga B., Serrano R., Ocana A. Targeting DNA repair in breast cancer: a clinical and translational update. Cancer Treat Rev 2010, 36:557-565.
64. O'Shaughnessy J., Miles D., Gray R.J., Dieras V., Perez E.A., Zon R., et al. Ameta-analysis of overall survival data from three randomized trials of bevacizumab and first line chemotherapy as treatment for patients with metastatic breast cancer. JClin Oncol 2010, 28. 15s abstract 1005.
65. Carey L.A., Rugo H.S., Marcom K., Irvin W., Ferraro M., Burrows E., et al. TBCR:001 EGFR inhibition with cetuximab added to carboplatin in metastatic triple negative (basal like) breast cancer. JClin Oncol 2008; May 20, suppl abstract 1009.
66. O'Shaughnessy J., Weckstein D., Vukelja S.J., McIntyre K., Krekow L., Holmes F.A., et al. Preliminary results of a randomised phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007, 106(suppl S32). abstract 308.
67. Baselga J., Gomez P., Awada A., Greil R., Braga S., Climent M.A., et al. The addition of cetuximab to cisplatin increases overall response rate in metastatic triple negative breast cancer: results of a randomized phase II study (BALI-1). ESMO 2010, abstract 2740.
68. Cleator S., Heller W., Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007, 8:235-244.
69. Gottipati P., Vischioni B., Schultz N., Solomons J., Bryant H.E., Djureinovic T., et al. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 2010, 70:5389-5398.
70. O'Shaughnessy J., Osborne C., Pippen J.E., Yoffe M., Patt D., Rocha C., et al. Iniparib plus chemotherapy in metastatic triple negative breast cancer. NEngl J Med 2011, 364:205-214.
71. Tutt A., Robson M., Garber J.E., Domchek S.M., Audeh M.W., Weitzel J.N., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
72. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose)polymerase in tumors from BRCA mutation carriers. NEngl J Med 2009, 361:123-134.
73. O'Shaugnessy J., Schwartzberg L.S., Danso M.A., Rugo H., Miller K., Yardley D.A., et al. Arandomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin in metastatic triple negative breast cancer. JClin Oncol 2011, 29. suppl; Abs 1007.
74. McGuire W.L. Breast cancer prognostic factors: evaluation guidelines. JNatl Cancer Inst 1991, 83:154-155.